MYND Life Sciences Inc. Share Price OTC Markets
Equities
MYNDF
CA62857B1094
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0249 USD | +17.45% | -.--% | -20.19% |
Sales 2022 | - | Sales 2023 | - | Capitalization | 7L 5.98Cr |
---|---|---|---|---|---|
Net income 2022 | -30L -25Cr | Net income 2023 | -10L -8.34Cr | EV / Sales 2022 | - |
Net Debt 2022 | 2.59 215.69 | Net Debt 2023 | 3 250.21 | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.05
x | P/E ratio 2023 |
-0.47
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.17% |
1 day | +17.45% | ||
1 month | +17.45% | ||
3 months | +45.61% | ||
6 months | +24.50% | ||
Current year | -20.19% |
Managers | Title | Age | Since |
---|---|---|---|
John Campbell
CEO | Chief Executive Officer | 53 | 26/20/26 |
Lyle Oberg
FOU | Founder | 63 | 06/18/06 |
Founder | 65 | 06/18/06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 65 | 06/18/06 | |
Lyle Oberg
FOU | Founder | 63 | 06/18/06 |
John Campbell
CEO | Chief Executive Officer | 53 | 26/20/26 |
1st Jan change | Capi. | |
---|---|---|
+11.91% | 12TCr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr |
- Stock Market
- Equities
- MYND Stock
- MYNDF Stock